Aegerion (AEGR) Lomitapide Briefing Docs Posted; FDA Panel Says More Patients Needed to Rule Out Cancer Risk
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Join SI Premium – FREE
Aegerion (Nasdaq: AEGR) shares are higher following the FDA posting briefing docs for its lomitapide mesylate caps in 5-, 10-, and 20-mg doses today.
The meeting for lomitapide with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will be on October 17th.
In brief, the Committee said Aegerion needs more patients to rule out cancer risk.
Shares of Aegerion are up 7 percent in early trading Monday.
The meeting for lomitapide with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will be on October 17th.
In brief, the Committee said Aegerion needs more patients to rule out cancer risk.
Shares of Aegerion are up 7 percent in early trading Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abeona Therapeutics (ABEO) Receives FDA Complete Response Letter on Pz-cel
- Corcept Therapeutics (CORT) Reports Positive Results From Open-Label Portion of Phase 3 GRACE Trial
- Pfizer (PFE) Announces EC Approves EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
